EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunotherapy in B-Cell Acute Lymphoblastic Leukemia

Kara L Davis, Catherine C Yao, Jessica A O Zimmerman, Rachel E Rau

Journal of the National Comprehensive Cancer Network · 2025-12 · 23 (12)

DOI: 10.6004/jnccn.2025.7067 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025-12. Verfasst von Kara L Davis und 3 weiteren Autor:innen. Beteiligte Einrichtung: 1Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Stanford University, Palo Alto, CA. Hauptthemen laut MEDLINE: Immunotherapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 186 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, immunotherapy has been increasingly incorporated into the clinical care of both pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) to improve outcomes. Four main categories of immunotherapies are used in B-ALL: (1) unconjugated monoclonal antibodies (mAbs), (2) antibody–drug conjugates (ADCs), (3) T-cell–engaging antibodies, and (4) CAR T cells. Although mAbs such as rituximab are primarily used in adults, the other modalities have demonstrated efficacy in both pediatric and adult patients with B-ALL. Among ADCs, inotuzumab ozogamicin (InO) has proven effective as monotherapy for relapsed disease, leading to FDA approval for patients aged >1 year with relapsed/refractory B-ALL. InO is also being investigated in the upfront setting in combination with chemotherapy. Although results in adults have been promising, increased rates of infectious complications in chemotherapy courses post-InO have hampered progress of trials in children, adolescents, and young adults. T-cell–engaging antibodies are now a standard component of therapy for most patients with newly diagnosed and relapsed B-ALL, following the successful integration of the bispecific T-cell–engager blinatumomab into chemotherapy regimens for both adults and children. Recent studies support the possibility of using blinatumomab to replace some or even most of the intensive chemotherapy traditionally used in B-ALL treatment. CAR T-cell therapy has revolutionized the treatment of relapsed/refractory B-ALL by targeting CD19, but challenges remain due to the loss of CAR T-cell persistence and antigen escape. Newer CAR T cells targeting CD22 or the combination of CD19 and CD22 are being studied to address the issue of antigen escape. Overall, immune-based therapies are now a mainstay of B-ALL therapy. This article reviews the efficacy and safety data of several immune-based therapies in B-ALL and discusses a number of outstanding questions and possible future directions for the use of immune-based approaches in the treatment of B-ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Agents, ImmunologicalHumansImmunoconjugatesImmunotherapy, AdoptiveTreatment OutcomeSialic Acid Binding Ig-like Lectin 2

Substanzen

Antineoplastic Agents, ImmunologicalImmunoconjugatesSialic Acid Binding Ig-like Lectin 2

Autor:innen und Institutionen

  • 1Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Stanford University, Palo Alto, CA.
  • 2Department of Pediatrics, Stanford University School of Medicine, Stanford University, Stanford, CA.
  • 3Division of Pediatric Hematology/Oncology/BMT, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA.
  • 4Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Hospital, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
  • 5Department of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.

Zitieren

APA

Davis, K. L., Yao, C. C., Zimmerman, J. A. O., & Rau, R. E. (2025). Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. Journal of the National Comprehensive Cancer Network, 23(12). https://doi.org/10.6004/jnccn.2025.7067

Vancouver

Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. Journal of the National Comprehensive Cancer Network. 2025;23(12). doi:10.6004/jnccn.2025.7067

BibTeX
@article{Davis2025,
  author = {Davis, Kara L and Yao, Catherine C and Zimmerman, Jessica A O and Rau, Rachel E},
  title = {Immunotherapy in B-Cell Acute Lymphoblastic Leukemia},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2025},
  volume = {23},
  number = {12},
  doi = {10.6004/jnccn.2025.7067}
}
Kostenlos starten →